Can I import peptides for personal use into Hong Kong?

Personal import of prescription medicines is permitted in limited quantities with a valid doctor's prescription. The medicine must not be a dangerous drug (separately scheduled under Cap. 134) and should be for personal use only. Unregistered products may be imported if genuine and accompanied by a prescription. Larger quantities require an import licence from the Drug Office.

Is Wegovy available in Hong Kong?

Yes, Wegovy (semaglutide 2.4mg injection) was registered in Hong Kong in April 2024 (HK-68222). It is available by prescription at registered pharmacies. Mounjaro (tirzepatide) was also registered in 2024 (HK-68703). Both are Part I poisons requiring a doctor's prescription.

Are there penalties for selling peptides illegally in Hong Kong?

Yes. The Drug Office actively prosecutes illegal sellers. In 2024-2025, multiple individuals were arrested for selling unregistered semaglutide and tirzepatide injections online. Penalties under the Pharmacy and Poisons Ordinance include fines and imprisonment. The Drug Office and Customs conduct joint enforcement operations.

Legal Disclaimer

This page provides general legal orientation for Hong Kong, not legal advice. Regulations change frequently. Always verify current rules with Department of Health and consult a qualified professional.

Peptide Legal Status in Hong Kong

Moderate

Hong Kong regulates pharmaceuticals under the Pharmacy and Poisons Ordinance (Cap. 138). GLP-1 agonists are classified as Part I poisons — requiring sale at registered pharmacies under pharmacist supervision with a doctor's prescription. The Drug Office has conducted multiple enforcement operations against illegal online sales of unregistered semaglutide and tirzepatide injections (2024-2025). Wegovy and Mounjaro were registered in Hong Kong in 2024. Personal import of prescription medicines is permitted in limited quantities with a valid prescription.

Regulator

Department of Health (Drug Office) — Official website

Key Facts

Regulatory Stance

moderate

Compounding Allowed

Yes

Telehealth Prescribing

Yes

Compounding Pharmacy Rules

Compounding is permitted by registered pharmacists under the Pharmacy and Poisons Regulations for individual patients with valid prescriptions. Standards follow British Pharmacopoeia guidelines. Large-scale compounding requires a manufacturer's licence from the Pharmacy and Poisons Board.

Telehealth Prescribing

The Medical Council of Hong Kong (MCHK) has issued Ethical Guidelines on Telemedicine. Doctors may prescribe via teleconsultation provided a proper doctor-patient relationship is established and clinical assessment is appropriate. Prescription-only medicines like GLP-1 agonists still require a valid prescription — online questionnaire-only prescribing without proper consultation may be investigated.

Peptide Categories in Hong Kong

Approved

Semaglutide — Ozempic (HK-64374), Wegovy (HK-68222, registered April 2024), Rybelsus. Tirzepatide — Mounjaro (HK-68703, registered April 2024). Liraglutide — Saxenda. All registered as Part I poisons, prescription-only at authorized sellers of poisons (registered pharmacies).

Research / Unapproved

BPC-157, TB-500, GHRPs — not registered as pharmaceutical products. Sale, possession for sale, or advertising of unregistered pharmaceutical products is illegal under Cap. 138. The Drug Office actively monitors online platforms and social media for illegal sales.

Banned / Restricted

Unregistered pharmaceutical products. Part I poisons sold without prescription. The Drug Office and Customs conduct joint operations — individuals have been arrested for selling unregistered semaglutide and tirzepatide injections online (2024-2025).

Key Legislation

Pharmacy and Poisons Ordinance (Cap. 138)
Dangerous Drugs Ordinance (Cap. 134)
Undesirable Medical Advertisements Ordinance (Cap. 231)

Peptides in Hong Kong: FAQ

Sources

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Peptide Laws in Other Countries

United Kingdom Canada Australia European Union Singapore United Arab Emirates New Zealand Germany Netherlands France Spain Japan South Korea

Get international legal updates

Stay informed when country-specific legal pages, routing guidance, and safety guidance change.

Free DownloadInternational Peptide Legal GuideGet our free quick reference covering peptide regulations across 14 countries — GLP-1 status, compounding rules, and telehealth access at a glance.PDF

No spam. Unsubscribe anytime.